Jump Trading’s Unity Biotechnology UBX Stock Holding History

Jump Trading’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,147	Closed	-$174K	–	577
2019 Q1	$174K	Buy	+2,147	New	+$243K	0.06%	407

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jump Trading's UBX Position: Q2 2019 in Review

Jump Trading sold out of Unity Biotechnology (UBX) in Q2 2019, closing a stake of 2,147 shares — an estimated $174K sold.

Jump Trading first reported a position in UBX in Q1 2019 and held it in 1 quarter. The position peaked at $174K in Q1 2019. 58 funds tracked by Wall St. Rank hold UBX as of Q2 2019.

Jump Trading reported no remaining Unity Biotechnology position as of Q2 2019 after selling out during the quarter.
Jump Trading sold 2,147 Unity Biotechnology shares in Q2 2019, an estimated $174K.
Jump Trading first reported a position in Unity Biotechnology in Q1 2019 and held it in 1 quarter.
Jump Trading's Unity Biotechnology position peaked at $174K in Q1 2019.
58 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2019.

Based on Jump Trading's 13F filing for Q2 2019, filed 14 Aug 2019.